Guildford, UK, 7 May 2014: ReNeuron Group plc (the “Company”) (AIM: RENE.L) today provides a further update on the PISCES Phase I clinical trial of its ReN001 stem cell therapy for disabled stroke patients ahead of the commencement of a Phase II efficacy study for which patient enrolment has now opened.